Información de la revista
Vol. 15. Núm. 4.
Páginas 171-173 (enero 2003)
Vol. 15. Núm. 4.
Páginas 171-173 (enero 2003)
Acceso a texto completo
Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia
Efecto de la atorvastatina y el bezafibrato en las concentraciones plasmáticas de proteína C reactiva en la hiperlipemia combinada (mixta)
Visitas
1046
J.A. Gómez-Gerique, E. Ros, J. Oliván, J.M. Mostaza, M. Vilardell, X. Pintó, F. Civeira, A. Hernández, P. Marques da Silva, A. Rodríguez-Botaro, D. Zambón, J. Lima, C. Díaz, R. Aristegui, J.M. Sol, J. Chaves, G. Hernández, Atomix investigators, J. Puzo
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía general
[Albert, 2002]
C.M. Albert, J. Ma, N. Rifai, M.J. Stampfer, P.M. Ridker.
Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death.
Circulation, 105 (2002), pp. 2595-2599
[Grundy, 2001]
S.M. Grundy, R.B. D’Agostino Sr, L. Mosca, G.L. Burke, P.W. Wilson, D.J. Rader, et al.
Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop.
Circulation, 104 (2001), pp. 491-496
[Koenig, 1999]
W. Koenig, M. Sund, M. Froelich, H.G. Fischer, H. Lowel, A. Doring, et al.
C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
Circulation, 99 (1999), pp. 237-242
[Mendall, 2000]
M.A. Mendall, D.P. Strachan, B.K. Butland, L. Ballam, J. Morris, P.M. Sweetman, et al.
C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men.
Eur Heart J, 21 (2000), pp. 1584-1590
[Ridker, 2001]
P.M. Ridker.
Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial.
Eur Heart J, 22 (2001), pp. 2135-2137
[Ridker, 1997]
P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens.
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
N Engl J Med, 336 (1997), pp. 973-979
[Ridker, 2000]
P.M. Ridker, C.H. Hennekens, J.E. Buring, N. Rifai.
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
N Engl J Med, 342 (2000), pp. 836-843
[Ridker, 2001]
P.M. Ridker, N. Rifai, M. Clearfield, J.R. Dows, S.E. Weis, J.S. Miles, et al.
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
N Engl J Med, 344 (2001), pp. 1959-1965
[Ridker, 2002]
P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, N.R. Cook.
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
N Engl J Med, 14 (2002), pp. 1557-1565
[Ross, 1999]
R. Ross.
Atherosclerosis — an inflammatory disease.
N Engl J Med, 340 (1999), pp. 115-126
[Tracy, 1997]
R.P. Tracy, R.N. Lemaitre, B.M. Psaty, D.G. Ives, R.W. Evans, M. Cushman, et al.
Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 1121-1127
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.